Post-Translational Modification and Regulation of the Chaperone Hsp27 during Apoptosis

A Senior Honors Thesis

Presented in Partial Fulfillment of the Requirements for graduation with research distinction in Molecular Genetics in the undergraduate colleges of The Ohio State University

by

Eric Joseph Murnan

The Ohio State University
June 2009

Project Adviser: Associate Professor Andrea Doseff, Department of Molecular Genetics, Department of Internal Medicine
INDEX

CHAPTER 1: INTRODUCTION

1.1 Apoptosis 3
1.2 Flavonoids 6
1.3 The small heat shock protein Hsp27 8

CHAPTER 2: MATERIALS AND METHODS

2.1 Materials and cell culture 13
2.2 Immunoblot and coomassie staining 13
2.3 Caspase-3 activity assay 14
2.4 Immunoprecipitation and in vitro kinase assay and phosphorylation of recombinant Hsp27 15
2.5 Bacterial cell culture 15
2.6 DNA purification and restriction enzyme digestion 16
2.7 Fragment isolation 16
2.8 DNA ligation 16
2.9 Transformation into E.Coli cells 17
2.10 Hsp27 purification under denaturing conditions 17
2.11 Transient transfection 18
2.12 Flow cytometry 19
2.13 Statistical analysis 19
CHAPTER 3: REGULATION OF HSP27 PHOSPHORYLATION DURING APIGENIN-INDUCED APOPTOSIS

3.1 Hsp27 exhibits a bimodal phosphorylation profile during apigenin-induced apoptosis. 21

3.2 Apigenin induces the activation of p38, ERK, and PKCδ. 21

3.3 Hsp27 phosphorylation is p38-dependent following 15 min apigenin treatment. 26

3.4 Hsp27 phosphorylation following 6 h apigenin treatment is characterized by residue specificity and dual pathways. 26

3.5 The effect of PKCδ on Hsp27 phosphorylation is independent of ERK activation 31

3.6 Generation of the PKCδ constitutively active catalytic fragment is not necessary for Hsp27 phosphorylation. 36

CHAPTER 4: ROLE OF HSP27 PHOSPHORYLATION DURING APIGENIN-INDUCED APOPTOSIS

4.1 Introduction of Hsp27 mutants into the 6xHis-tagged expression vector pQE32 and protein purification under denaturing conditions. 40

4.2 Phosphorylation of Hsp27 is not required for Hsp27’s ability to protect against apigenin-induced mitochondrial membrane depolarization. 43

CHAPTER 5: DISCUSSION 47

ACKNOWLEDGEMENTS 53

REFERENCES 54
1.1 Apoptosis

Apoptosis, or programmed cell death (PCD), is an essential mechanism for the regulation of cellular homeostasis and normal development. Apoptosis requires precise regulatory and signaling pathways to orchestrate the timing and progression of cell death. Among the processes dependent upon apoptosis are organ formation and regulation of the immune system, as well as successful completion of embryo development (1, 2). Apoptosis is characterized by various biochemical and morphological changes, including DNA fragmentation, plasma membrane blebbing, and the externalization of signaling molecules such as phosphatidylserine, which lead to the formation of apoptotic bodies (3). Of particular importance is the deregulation of apoptosis. The failure of a cell to undergo apoptosis is central to cancer progression and chronic inflammatory diseases. On the contrary, uncontrolled apoptosis may lead to neurodegenerative diseases such as Parkinson’s and Alzheimer’s (4-6).

Apoptosis is executed by a family of conserved cysteine proteases called caspases. Caspases involved in apoptosis are characterized into two groups, the initiator caspases, such as caspase-8 and caspase-9, and the effector caspases, such as caspase-3 and caspase-7. All caspases are synthesized in cells as inactive precursors called pro-caspases that become activated by various apoptotic stimuli (7-9). Activation is induced through a series of proteolytic cleavages that result in an assembly of tetramers. The activation of an effector caspase is performed by an initiator caspase through an internal
cleavage to separate the large and small subunits. The activation of an initiator caspase, however, is autoactivated under apoptotic conditions and usually facilitated by large multicomponent complexes often called apoptosomes (10). The active enzymes are heterotetramers composed of two identical subunits of ~20 kDa and two identical subunits of ~10 kDa, whereas the prodomain or amino-terminal domain is usually cleaved during activation (11). Initiator caspases typically contain an extended N-terminal prodomain that is important for protein-protein interactions. In contrast, effector caspases typically contain a shortened prodomain often implicated in binding to regulatory proteins (12). All known caspases possess an active-site cysteine, and cleave substrates after aspartic residues at Asp-Xxx bonds; the distinct substrate specificity of caspases is determined by the four residues amino-terminal to the cleavage site (13). Cleavage induces activation or inactivation of substrates that results in the characteristic biochemical changes that progress cells towards death through the formation of apoptotic bodies (3).

Two main pathways exist for caspase activation: the extrinsic pathway and the intrinsic pathway. The extrinsic pathway, or the receptor mediated-pathway, involves the binding of apoptotic stimuli to a receptor, such as the Fas receptor, that contains a cytoplasmic death domain essential for transduction of the apoptotic stimuli. Receptor-ligand association promotes the formation of an intracellular complex of adaptor proteins including FADD (Fas-associated death domain) which triggers the recruitment of pro-caspase-8 and the subsequent activation of the caspase cascade (14, 15). In contrast, the intrinsic pathway is receptor-independent and is commonly initiated by mitochondrial dysfunction. Apoptotic stimuli, such as cytotoxic drugs, produce changes in the
mitochondrial membrane potential which allows for the leakage of pro-apoptotic molecules such as cytochrome c, into the cytoplasm, promoting the activation of caspase-9. Released cytochrome c binds to Apaf-1 and the cofactor dATP, resulting in the formation of the apoptosome. Together, these molecules allow for the activation of caspase-9 (16). The activation of caspase-9 can also be accomplished through the receptor-mediated pathway following the activation of caspase-8 (17) serving as a means of communication between the intrinsic and extrinsic apoptotic pathways. In addition to cytochrome c, radical oxygen species (ROS) are often released from the mitochondria due to disruption of the electron transport chain (18) and contribute to the activation of the apoptotic program (19). Regardless of the pathway, however, signaling cascades converge on the activation of downstream effector caspases such as caspase-3, -6, and -7 (20), which are collectively responsible for the cleavage of target proteins and the subsequent biochemical changes accompanying apoptosis (21-23).

In addition to caspase activation, cell response to apoptotic-inducing drugs has been associated with the activation of apoptotic kinases and the inactivation of survival kinases. The mitogen-activated protein kinase family (MAPK), which includes p38, JNK (Jun-N-terminal kinase), and ERK (extracellular signal-regulating kinase), has been implicated in cell proliferation, cell survival, and stress response (24). For instance, activation of p38 is associated with the induction of apoptosis in response to UV treatment and treatment with chemotherapeutic drugs (25, 26). By contrast, ERK can exhibit either anti-apoptotic or pro-apoptotic functions depending on the stimuli and cell type. In monocytes, ERK phosphorylation has been shown to inhibit caspase-9 activation and therefore apoptosis (27). However, up-regulation of ERK is associated with
apoptosis, especially during treatment with flavonoids (28). In addition to MAPKs, members of the protein kinase C family (PKC) have been shown to regulate cell death. In particular, PKCδ has been suggested as a pro-apoptotic molecule as PKCδ activation has been associated with cell death in various cell types in response to a variety of apoptotic stimuli (29). For instance, PKCδ has been shown to phosphorylate and activate caspase-3 (30). PKCδ has also been identified as a substrate of caspase-3 and its proteolytic cleavage results in a constitutively active catalytic domain necessary for apoptosis (31, 32). Additionally, PKCδ has been shown to translocate to the mitochondria and alter its membrane potential (33) and promote ROS production (34, 35).

1.2 Flavonoids

Increasing attention has been focused on the use of compounds derived from fruits and vegetables for epidemiological purposes such as cancer prevention and oxidative stress protection. The principal plant-derived agents thought to provide cancer prevention and antioxidant properties are flavonoids, which are the most common and widely distributed polyphenolic compounds, ubiquitously present in foods of plant origins (36). Flavonoids are composed of a common phenyl chromanone structure with one or more hydroxyl substitutes (Fig 1.1). Depending on the organization of their benzene rings and their modifications, flavonoids are generally classified into flavones, flavanols, isoflavones, flavanols, flavanones, and anthocyanins (36, 37). Flavonoids have long been recognized as having anti-cancer, anti-inflammatory, anti-viral, anti-bacterial, and anti-allergic properties (38-40). For example, the flavanone naringenin, which is found abundantly in grapefruits, has been shown to have an anti-
Figure 1.1 Structure of typical flavonoid (top) and apigenin (bottom)
carcinogenic effect in breast cancer (41). The flavone apigenin, which is found abundantly in broccoli, parsley, and chamomile tea, has been reported to induce apoptosis in breast cancer, colon cancer and lymphocytic leukemia (42-44). In particular, apigenin has been shown to induce mitochondrial depolarization and the production of reactive oxygen species which allows for the release of cytochrome c and procaspase-9 from the mitochondria and the induction of the caspase-dependent apoptotic pathway (44-46). Recently, a role for apigenin in monocytic leukemia cells was identified. It was shown that apigenin localizes to the mitochondria of leukemia cells and stimulates the apoptotic pathway in a PKCδ and caspase-dependent mechanism. However, in contrast to many other cell types, ROS production and MAPK activation were shown to act independently of apoptosis induction (47). In addition, there is very little evidence to suggest that apigenin produces adverse metabolic effects when consumed in nutritionally relevant quantities. In fact, it has been shown that apigenin reduces proliferative properties of leukemia cells at a much greater capacity than the flavonoid’s effect on the epithelial cells MCF7 and A549 (47). Therefore, the use of apigenin as a chemopreventive agent may provide a tissue-specific defense against cancer and oxidative stress.

1.3 The small heat shock protein Hsp27

The small heat shock protein 27 (Hsp27) belongs to a family of molecular chaperones that have recently been focused on as regulators of cell death and survival. Hsps encompass several groups of proteins and are classified by size, structure, and function: Hsp110, Hsp90, Hsp70, Hsp60, and the small Hsp families (48). Some Hsps are constitutively expressed and increase in response to environmental and physiological
stress. In unstressed cells, Hsps are essential for maintaining cellular homeostasis, functioning as molecular chaperones to help facilitate protein folding (49-51).

The small heat shock proteins (sHsps) are low molecular mass chaperones ubiquitously present throughout all kingdoms. The sHsps are ATP-independent chaperones characterized by a conserved crystallin domain flanked by variable N- and C-terminal regions (52, 53). In unstressed cells, sHsps exist as large oligomeric complexes whose oligomerization state is dependent on the degree of phosphorylation of the individual monomers. Phosphorylation at the N-terminus results in a redistribution of the large oligomer into smaller tetramer units whereas dephosphorylation promotes the formation of large oligomers (54, 55). It is thought that the chaperone activity of sHsps is correlated with this dynamic oligomerization. Exposure to stress promotes the formation of misfolded proteins that may bind large non-phosphorylated sHsp oligomers or smaller complexes such as dimers to prevent aggregation. Upon return to favorable conditions, these proteins are released and either refold spontaneously or with the help of the ATP-dependent chaperones such as Hsp70 (56).

More recently, focus has shifted towards the potential anti-apoptotic functions of the sHsps, with a particular emphasis on Hsp27. Hsp27 is known to block apoptosis at different stages due to its interaction with other proteins. As a molecular chaperone, Hsp27 plays an important role in the prevention of protein aggregates following misfolding. Sufficiently large amounts of misfolded proteins can result in the formation of these aggregates, which can signal for the induction of apoptosis (50, 51). Hsp27 can also protect against protein aggregation at the pre-translational level by binding to the translation initiation factor eIF4G and preventing the translation of mRNAs under
stressful conditions, a common cause of protein misfolding (49). Additionally, Hsp27 has been shown to protect against apoptosis by regulating mitochondrial dysfunction through inhibition of ROS production and mitochondrial membrane depolarization (34, 57-59).

However, Hsp27 primarily exhibits its anti-apoptotic effect through direct interaction with several critical components of the apoptotic pathway (Fig 1.2). Following extrinsic stimuli, Hsp27 has been shown to exhibit its anti-apoptotic effect in a mitochondrial and caspase-independent manner by blocking the interaction of Daxx with the Fas death receptor (60). More importantly, Hsp27 functions as a negative regulator of the leakage of pro-apoptotic molecules normally residing in the mitochondria, which can result in caspase-3-dependent apoptosis. Hsp27 inhibits caspase-3 activation by sequestering pro-caspase-3 and cytochrome c (61), negatively regulating the activation of the pro-caspase-9 through interaction with cytochrome c (62), and inhibiting the activation of the pro-apoptotic Bax through a PI3K-dependent mechanism (63). Hsp27 has also been shown to regulate apoptosis by binding to the prodomain of caspase-3, inhibiting its activation (64). Thus, Hsp27 exhibits a robust anti-apoptotic activity with many members of the apoptotic pathway and many potential points of regulation.

It is recognized that interaction of Hsp27 with other proteins is regulated by the oligomerization and phosphorylation status of the protein. It has been suggested that large non-phosphorylated oligomers of Hsp27 are required for its caspase-dependent anti-apoptotic activity (65). Moreover, it has been shown that phosphorylation is responsible for the release of Hsp27 from its target proteins through dissociation into smaller multimers (55, 66). Hsp27 is phosphorylated at three different serine residues, Ser-15, Ser-78, and Ser-82, by mitogen-activated protein kinase-activated protein kinase 2 (MK2).
Hsp27 can regulate apoptosis various points. Following extrinsic activation of the apoptotic pathway, Hsp27 can block Daxx-mediated apoptosis by preventing the translocation of Daxx to the plasma membrane and its association with the Fas receptor. Hsp27 also acts as a negative regulator of the leakage of pro-apoptotic molecules from the mitochondria by maintaining intracellular redox homeostasis and mitochondrial stability. Following stress-induced release of pro-apoptotic molecules from the mitochondria, Hsp27 can inhibit Bax in a PI3K-dependent mechanism and sequester cytochrome c release from the mitochondria. In addition, Hsp27 can regulate caspase activation both by preventing caspase-9 activation by association with cytochrome c and by binding to the prodomain of caspase-3.
as a result of p38 MAPK pathway activation (67, 68). Additionally, it has been found that PKCδ may act as an upstream kinase of p38, inducing the phosphorylation of Hsp27 by MK2 (69), or as the kinase directly responsible for Hsp27 phosphorylation (66, 70). Although p38 has been identified as the primary upstream kinase involved in MK2 activation, other families of MAPKs may play a role in Hsp27 phosphorylation. In particular, ERK has been identified as both a kinase responsible for MK2 phosphorylation (71) and a substrate of PKCδ (72). Therefore, the kinases involved in Hsp27 phosphorylation may exhibit both cell and stimulus specificity.

In this work, we sought to determine the regulators of Hsp27 phosphorylation during apigenin-induced apoptosis. Additionally, we sought to determine the role of Hsp27 phosphorylation in the chaperone’s ability to protect against mitochondrial membrane depolarization. We first demonstrated that Hsp27 exhibits a bimodal phosphorylation during apigenin-induced apoptosis. We found that following a 15 min apigenin treatment, Hsp27 phosphorylation is p38 dependent. Additionally, we found that at 6 h post-apigenin treatment, Hsp27 phosphorylation at both Ser-78 and Ser-82 is p38 dependent. Moreover, we found that at 6 h, only Ser-82 is PKCδ dependent and full-length PKCδ can directly and specifically phosphorylate Hsp27 at Ser82. Furthermore, we found that p38 may act upstream of PKCδ during this phosphorylation event. Finally, we found that protection against mitochondrial depolarization is independent of Hsp27 phosphorylation. Collectively, these results suggest an intimate association among p38, PKCδ, and Hsp27 and uncover a novel bimodal phosphorylation pattern in Hsp27, further elucidating the mechanism by which apigenin regulates cell death.
CHAPTER 2
MATERIALS AND METHODS

2.1 Materials and cell culture

All cell lines were grown at 37 °C in a humidified atmosphere of 95% air and 5% CO₂ in media supplemented with 100 μg/mL penicillin, and 100 μg/mL streptomycin (P/S; BioWhittaker, Walkersville, MD). Monocytic leukemia THP-1 cells were maintained in RPMI 1640 medium with L-glutamine (BioWhittaker) supplemented with 5% fetal bovine serum (FBS) (Hyclone, Logan, UT). For all experiments, cells were seeded at a concentration of 0.5 x 10⁶ cells/mL 24 h prior to treatment. Apigenin, the diluent dimethyl sulfoxide (DMSO), the phosphatase inhibitors: Na-glycerophosphate, Na-pyrophosphate, NaF, orthovanadate; dithiothreitol (DTT), and the protease inhibitors: phenylmethyl sulfon fluoride (PMSF), chymostatin, pepstatin, leupeptin, antipain were obtained from Sigma-Aldrich (St. Louis, MO). The substrate of caspase-3, DEVD-AFC (AFC138), and the caspase-3 inhibitor, DEVD-FMK (FMK109), were obtained from MP Biomedicals (Solon, OH). The inhibitors of p38, SB203580 (559389), MEK-1, PD98059 (513000), and the PKCδ inhibitor, rotterlin (557370), were obtained from Calbiochem (San Diego, CA).

2.2 Immunoblot and coomassie staining

Whole cell lysates were prepared by vortexing in Buffer B (50 mM HEPES pH 7.4, 2.5 mM EGTA, 1 mM EDTA, 150 mM NaCl, 10% Glycerol, 0.1% Tween 20 containing 50 mM NaF, 10 mM Na glycerophosphate, 5 mM Na pyrophosphate, 1 mM orthophosphate, 1 mM DTT, 0.1 mM PMSF, 2 μg/ml of protease inhibitors: chymostatin,
pepstatin, leupeptin, antipain and phosphatase inhibitors) for 1 h at 4 °C. Lysates were then centrifuged at 13,200 x g for 10 min at 4 °C. Supernatants were removed from pellets and stored at -80 °C until further analysis. Polypeptides from equal amounts of protein, as determined by the Bradford method, were separated by SDS-PAGE. Gels were stained over night with Coomassie stain (0.025% (w/v) Coomassie G-250, 45% (v/v) methanol, 10% (v/v) glacial acetic acid) followed by destaining solution (30% (v/v) methanol, 10% (v/v) glacial acetic acid). For immunoblot analysis, polypeptides were transferred onto nitrocellulose membranes (25 mM Tris, pH 8.3, 192 mM glycine, 20% (v/v) methanol) and probed with antibodies of interest followed by horseradish peroxidase conjugated secondary antibody and visualized by enhanced chemiluminescence (Amersham, Arlington Heights, IL). Immunoblot quantitation was performed with Biorad Quantity One software (Hercules, CA). Phospho-ERK (9101), total ERK (9102), phospho-p38 (9211), total p38 (9212), phospho-Hsp27 (Ser78) (2405), phospho-Hsp27 (Ser82) (2401), and total Hsp27 (2442) antibodies were obtained from Cell Signaling (Boston, MA). PKCδ antibody (SC-937) was obtained from Santa Cruz Biotechnology (Santa Cruz, CA). β-Tubulin (05-661) was obtained from Upstate (Charlottesville, VA).

2.3 Caspase-3 activity assay

Lysates from 3 x 10^6 cells were prepared and incubated in a cytobuffer as previously described (27). The activity of caspase-3 in a 10 μg protein sample was determined using the DEVD-AFC substrate. Released AFC were measured using a
Cytofluor 400 fluorimeter (Filters: excitation 400 nm, emission 508 nm; Perspective Co., Framingham, MA).

2.4 Immunoprecipitation and in vitro kinase assay and phosphorylation of recombinant Hsp27

Following treatment with apigenin or DMSO, lysates were prepared as described for immunoblot analysis. Immunoprecipitation with anti-PKCδ antibodies were carried out as previously described (30). After immunoprecipitation, kinase assays were performed by incubating protein A-loaded beads for 1 h at 37 °C in the presence of 20 μl kinase assay buffer (25 mM Hepes pH 7.3, 10 mM MnCl₂, 1 mM MgCl₂, 1 mM DTT) containing 5 μCi of {γ³²P} ATP (Perkin Elmer, Boston, MA), 0.5 mM ATP. To each reaction, 5 μg of histone H2B (Boehringer Mannheim, Roche, Indianapolis, IN) was added as exogenous substrate. Reactions were stopped by the addition of 10 mL of 5X Laemmli buffer. Samples were boiled for 5 min and loaded onto SDS-PAGE.

For phosphorylation of recombinant Hsp27, recombinant PKCδ or heat-inactivated recombinant PKCδ was incubated with recombinant wild-type Hsp27 for 1 h at 30 °C in the presence of 10 μL of kinase assay buffer containing 10 μCi of {γ³²P} ATP.

2.5 Bacterial cell culture

Bacterial cells containing selected clones were cultured overnight at 37°C at 200 rpm in 3-5 mL of LB media containing an appropriate putative antibiotic for selection.
2.6 DNA purification and restriction enzyme digestion

Plasmid DNA was purified (45) for screening and transfections using QIAprep Miniprep Kit (QIAGEN, Valencia, CA) and eluted in 50 μL dH₂O. Plasmids were digested with combinations of restriction enzymes (NEB, Beverly, MA) in bovine serum albumin (NEB, Beverly, MA), enzyme reaction buffer, (NEB, Beverly, MA), and dH₂O for 2 hrs at 37 °C.

2.7 Fragment isolation

DNA was run on a 1% (w/v) agarose gel (Roche, Basel, Switzerland) containing ethidium bromide (0.5 μg/μL) (Sigma Aldrich Corp., St. Louis, MO) to stain the DNA. DNA was loaded with a 1 kb plus marker (Invitrogen, Carlsbad, CA) and electrophoresed for 40 min at 80 volts. Fragments were purified from the agarose using a DNA gel extraction kit (QIAGEN).

2.8 DNA ligation

Vector and insert DNA were ligated to create a desired chimeric plasmid. Purified DNA insert fragments and vector were combined in a 2 to 1 ratio with T4 DNA ligase (1 U/μL) (Roche, Basel, Switzerland), T4 ligase reaction buffer [50 mM Tris-HCL, (pH 7.5), 10 mM MgCl₂, 10 mM DTT, 1 mM ATP, 20 μg/ml BSA] (Roche, Basel, Switzerland) and dH₂O in a 10 μL volume and incubated overnight at 16 °C.
2.9 Transformation of *E. coli*

Amplification of clones was carried out by transforming into 50 μL *E. coli* Top10F competent cells (Invitrogen). Transformations were performed by combining ligation mixture (DNA, T4 ligase, ligation buffer, H2O) and cloning cells, *E. coli* Top10F for 30 min on ice. Heat shock was performed at 42 °C for 1 min followed by incubation on ice for 2 min. One mL S.O.C. media (2% Tryptone, 0.5% Yeast Extract, 10 mM NaCl, 2.5 mM KCl, 10 mM MgCl₂, 10 mM MgSO₄, 20 mM glucose) (Invitrogen) was added to mixture, and mixture was incubated at 37 °C and 200 rpm for 1 h. Cells were plated on LB-agar plates containing antibiotics specific to vector and grown overnight at 37 °C. Colonies were screened by restriction analysis of miniprep DNA.

2.10 Hsp27 purification under denaturing conditions

Bacteria containing 6xHis-tagged full-length Hsp27 3A (S15A, S78A, S82A) (pQE32-Hsp27 3A), or Hsp27 3D (S15D, S78D, S82D) (pQE32-Hsp27 3D) were grown in TB media with appropriate antibiotics and 2% (w/v) glucose to an OD of approximately A₅₅₀ 0.5. Protein expression was induced with 1mM IPTG for 3 h at 37 °C. Cells were collected and washed once in complete sonication buffer (50 mM sodium phosphate, pH 7.8, 300 mM NaCl, 5 mM β-mercaptoethanol, 1% Tween 20, and protease inhibitors (2 μg/mL chymostatin, pepstatin, leupeptin, antipain), and 1 mM PMSF). Cells were resuspended in buffer B (100 mM NaH₂PO₄, 10 mM Tris, 8 M urea, 1 μL/mL RNase and DNase, pH 8.0) and incubated for 30 min at rt. Cells were then sonicated until lysed. Lysates were allowed to bind to Ni²⁺-NTA beads (QIAGEN) in the presence of RNase and DNase (1 μL/mL) for 90 min at rt. After binding, the lysate-resin mixture was
loaded on an empty column and allowed to settle. The flow through was collected and the resin was washed twice with buffer C (100 mM NaH$_2$PO$_4$, 10 mM Tris, 8 M urea, 1 μL/mL RNase and DNase, pH 6.3). Elutions were collected dropwise with buffer D (100 mM NaH$_2$PO$_4$, 10 mM Tris, 8 M urea, 1 μL/mL RNase and DNase, pH 5.9) and buffer E (100 mM NaH$_2$PO$_4$, 10 mM Tris, 8 M urea, 1 μL/mL RNase and DNase, pH 4.5). Elution fractions containing recombinant Hsp27 were identified by SDS-PAGE. The purified proteins underwent two series of dialysis. The buffer for the first dialysis consisted of 25 mM NaH$_2$PO$_4$, 100 mM NaCl, 1% (v/v) Glycerol, 0.1 mM PMSF, pH 8.5. Dialysis was performed for 20 h at 4 °C, changing to fresh buffer after 3 h and again after 15 h. The buffer for the second dialysis consisted of 20 mM Tris pH 7.4, 10 mM NaCl, 1mM EDTA, 1 mM DTT. Dialysis was performed for 4 h at 4 °C, changing the buffer three times during that time. Proteins were quantitated using a BSA standard and identified by immunoblot analysis.

2.11 Transient Transfection

Transfection of plasmids into THP-1 monocytic cells was performed as previously described (64). THP-1 cells were washed in PBS and resuspended in the specified electroporation buffer (Amaxa, Cologne, Germany) to a final concentration of 5 x 10$^6$ cells/mL. One μg of empty vector (pCDNA3-5myc) and vector containing wild type full-length Hsp27 (pCDNA3-Hsp27-wt-FL-5myc), full-length Hsp27 3A (S15A, S78A, S82A) (pCDNA3-Hsp27-3A-FL-5myc), or Hsp27 3D (S15D, S78D, S82D) (pCDNA3-Hsp27-3D-FL-5myc) was mixed with 0.1 mL of cell suspension and nucleofected using the Amaxa Nucleofector™ according to manufacturer’s specification.
After transfection, the cells were immediately transferred into 3 mL of RPMI-medium with 10% (v/v) FBS and 1% (w/v) penicillin and streptomycin.

2.12 Flow Cytometry

Twenty-four hours after transfection, the cells were treated with 50 μM apigenin for 1 h to induce mitochondrial membrane depolarization. For detection of mitochondrial depolarization, a cell suspension was adjusted to a density of 1 x 10^5 cells/mL and incubated in annexin V binding buffer (BD Biosciences, Franklin Lakes, NJ) with 1% FBS for 15 min at room temperature in the dark with 5 μg/μL of the mitochondrial membrane potential specific fluorescent probe JC-1. Flow cytometry analysis was performed using BD Biosciences FACSCalibur using Cellquest version 3.3 software.

2.13 Statistical Analysis

All data are expressed as mean ± SEM and Student’s t-test comparisons were conducted to analyzed statistical significance. Statistical significance is stated in the text.
Phosphorylation is known to be a critical and ubiquitous post-translational protein modification. Essential in signal transduction, phosphorylation has also been implicated in regulation of various proteins through the induction of conformational changes. Of particular interest, the phosphorylation of Hsp27 is thought to induce the dissociation of large Hsp27 oligomers to smaller multimers and dimers (73) and affect the affinity of the protein for its substrates (74). Therefore, phosphorylation, and the regulation of this phosphorylation, may play a critical role in Hsp27’s anti-apoptotic activity. In this aim, we seek to determine the molecules responsible for regulating Hsp27 phosphorylation during apigenin-induced apoptosis.
3.1 Hsp27 exhibits a bimodal phosphorylation profile during apigenin-induced apoptosis.

It is known that Hsp27 becomes phosphorylated within minutes of exposure to stress (75) at three different serine residues, Ser-15, Ser-78, and Ser-82 with Ser-78 and Ser-82 being the most physiologically relevant phosphorylation sites (67, 68). In order to study the effect of apigenin on the phosphorylation status of Hsp27, we first determined the expression profile of phosphorylated Ser-78 and Ser-82 isoforms of Hsp27 during apigenin-induced apoptosis. For this purpose, THP-1 cells were treated with 50 μM apigenin for 0.25, 0.5, 1, 3, 6, and 9 h or with DMSO as diluent control for 9 h. Cell lysates were prepared and analyzed by immunoblot analysis. (Fig 3.1). We found that both phospho-Hsp27-S78 and phospho-Hsp27-S82 exhibit a bimodal expression profile during apigenin treatment. We observed that Hsp27 phosphorylation peaks at both serine residues 15 min post-apigenin treatment. Additionally, we also observed hyperphosphorylation at 6 h post-treatment following a period of diminished presence of the phosphorylated isoforms. Hsp27 is constitutively expressed and these levels remain constant throughout apigenin-induced apoptosis.

3.2 Apigenin induces the activation of p38, ERK, and PKCδ.

The involvement of the various members of the mitogen-activated protein kinase families, such as p38 and ERK, in promoting apoptosis is well characterized (76). Additionally, PKCδ is known to be a pro-apoptotic kinase in response to a variety of stimuli in a number of cell types (77). Therefore, these kinases may play yet uncharacterized roles during apigenin-induced apoptosis; in particular, through regulation of Hsp27. Phosphorylation of Hsp27 has been shown to be dependent upon p38
Figure 3.1 Hsp27 phosphorylation peaks at 15 min and 6 h following apigenin treatment

Lysates from THP-1 cells cultured with 50 μM apigenin for 0.25, 0.5, 1, 3, 6, and 9 h or with DMSO as diluent control. Immunoblots with phospho-Hsp27 Ser78, phospho-Hsp27 Ser82, total Hsp27, and β-Tubulin.
activation of MK2 (67), direct interaction with PKCδ (66), and a signaling pathway involving both PKCδ and p38 (69). Moreover, ERK may play a role in Hsp27 phosphorylation as it has been identified as both a kinase directly involved in the phosphorylation of MK2 (71) and as a substrate of PKCδ (72). Therefore, the nature of the kinases involved in Hsp27 phosphorylation may be stimulus specific. To investigate a potential role for these kinases in regulation of apigenin-induced Hsp27 phosphorylation, we first determined the expression profile of phospho-p38 and phospho-ERK following apigenin treatment. THP-1 cells were treated with 50 μM apigenin for different lengths of time or with DMSO as diluent control for 9 h. Cell lysates were prepared and analyzed by immunoblot analysis (Fig 3.2). We found that both p38 and ERK became hyperphosphorylated following apigenin treatment. As with Hsp27, we found that p38 phosphorylation exhibits a bimodal expression profile which peaks at 15 min and 6 h. In contrast, we found that ERK phosphorylation increased through 6 h where it plateaus. Our results indicate a similarity between phosphorylation of p38 and Hsp27 at both 15 min and 6 h post-apigenin treatment and between ERK and Hsp27 at 6 h post-treatment. Together these findings suggest potential roles for p38 and ERK in Hsp27 phosphorylation.

We next sought to determine the kinase activity of PKCδ during apigenin-induced apoptosis. THP-1 cells were treated with apigenin under similar conditions as above and cell lysates were prepared and analyzed by in vitro kinase assay to determine PKCδ’s ability to phosphorylate its substrate histone H2B (Fig 3.3). We found that PKCδ has maximal kinase activity 6 h post-apigenin treatment. In contrast, PKCδ has little kinase
Figure 3.2 p38 MAPK and ERK phosphorylation during apigenin-induced apoptosis

Lysates from THP-1 cells cultured with 50 μM apigenin for 0.25, .5, 1, 3, 6, and 9 h or with DMSO as diluent control. Immunoblots with phospho-p38, phospho-ERK, total p38, total ERK, and β-Tubulin.
Figure 3.3 Kinase activity of PKCδ during apigenin-induced apoptosis

Lysates from THP-1 cells cultured with 50 µM apigenin for 0.25, 0.5, 1, 3, 6, and 9 h or with DMSO as diluent control. Cells were immunoprecipitated (IP) with anti-PKCδ antibodies or an isotype control (IgG) and subjected to in vitro kinase assays in the presence of histone H2B and [γ32P]ATP. Phospholabeled proteins were visualized by autoradiography. Immunoblots with PKCδ served as IP-loading control.
activity prior to this time point. This result suggests a potential role for PKCδ in Hsp27 phosphorylation following 6 h apigenin treatment.

3.3 **Hsp27 phosphorylation is p38-dependent following 15 min apigenin treatment.**

Phosphorylation profiles of Hsp27 and p38 following apigenin treatment (Fig 3.1, Fig 3.2, respectively) indicate a potential role for p38 in the phosphorylation of Hsp27 at both 15 min and 6 h post-treatment. We first sought to determine the role of p38 in Hsp27 phosphorylation following a 15 min apigenin treatment. For this purpose, we aimed to determine the effects of pharmacological inhibition of p38 on Hsp27 phosphorylation 15 min post-apigenin treatment. THP-1 cells were pretreated with 10 μM of the p38 inhibitor SB203580 or with DMSO as diluent control for 1 h. Following pretreatment, cells were treated with 50 μM apigenin for 15 min. Cell lysates were prepared and analyzed by immunoblot analysis (Fig 3.4). We found that pretreatment with SB203580 prior to a 15 min apigenin treatment reduced Hsp27 phosphorylation at both Ser-78 and Ser-82, as well as p38 phosphorylation (lane 3). These results suggest the necessity for p38 activity in Hsp27 phosphorylation following a 15 min apigenin treatment.

3.4 **Hsp27 phosphorylation following 6 h apigenin treatment is characterized by residue specificity and dual pathways.**

Phosphorylation profiles of Hsp27 and p38 (Fig 3.1 and Fig 3.2, respectively) and the kinase activity of PKCδ (Fig 3.3) indicate potential roles for p38 and PKCδ in the phosphorylation of Hsp27 at 6 h post-apigenin treatment. Here we sought to determine
Figure 3.4 Hsp27 phosphorylation is p38 dependent following 15 min apigenin treatment

Lysates from THP-1 cells cultured with 50 µM apigenin for 15 min following 1 h pretreatment with 10 µM of the p38 pharmalogical inhibitor SB203580 (lane 3). Immunoblots with phospho-Hsp27 Ser78, phospho-Hsp27 Ser82, phospho-p38, total Hsp27, total p38 and β-Tubulin.
the role of p38 and PKCδ in Hsp27 phosphorylation following 6 h apigenin treatment. For this purpose, we first sought to determine the effects of pharmacological inhibition of p38 and PKCδ on Hsp27 phosphorylation 6 h post-apigenin treatment. THP-1 cells were pretreated with either 10 μM of the p38 inhibitor SB203580, 15 μM of the PKCδ inhibitor rottlerin, both SB203580 and rottlerin, or DMSO as diluent control for 1 h. Following pretreatment, cells were treated with 50 μM apigenin for 6 h. Cell lysates were prepared and analyzed by immunoblot analysis. We found that pretreatment with SB203580 prior to 6 h apigenin treatment significantly reduced Hsp27 phosphorylation at both Ser-78 (Fig 3.5, lane 3) and Ser-82 (Fig 3.6, lane 3), indicating the necessity for p38 activity in Hsp27 phosphorylation following 6 h apigenin treatment. In contrast, we found that pretreatment with rottlerin under similar conditions failed to reduce Hsp27 phosphorylation at Ser-78 (Fig 3.5, lane 4). However, rottlerin pretreatment prior to 6 h apigenin treatment significantly reduced Hsp27 phosphorylation at the Ser-82 residue (Fig 3.6, lane 4), implicating a role for PKCδ in Hsp27 phosphorylation in a residue-specific manner following 6 h apigenin treatment. As expected, pretreatment with the p38 inhibitor SB203580 and the PKCδ inhibitor rottlerin significantly reduced Hsp27 phosphorylation at both serine residues (Fig 3.5, Fig 3.6, lane 5).

Hsp27 is known to be phosphorylated by p38 through MK2. In contrast, it has been shown that PKCδ can directly phosphorylate Hsp27 (66, 70). Our results suggest that PKCδ may directly phosphorylate Hsp27 in a residue-specific manner following 6 h apigenin treatment. To test this hypothesis, recombinant PKCδ was incubated with recombinant wild-type Hsp27 and [γ32P]ATP and analyzed by immunoblot analysis.
Figure 3.5 Hsp27 phosphorylation at Ser-78 is p38 dependent following 6 h apigenin treatment

Lysates from THP-1 cells cultured with 50 µM apigenin for 6 h following 1 h pretreatment with 10 µM of the p38 pharmalogical inhibitor SB203580 (lane 3), the PKCδ inhibitor rottlerin (lane 4), or both (lane 5). Immunoblots with phospho-Hsp27 Ser-78 and total Hsp27. Densitometry data normalized by the loading control is represented as Mean ± SEM (N=6, * p ≤ 0.01, NS denotes non-statistical significance)
**Figure 3.6 Hsp27 phosphorylation at Ser-82 is p38 and PKCδ dependent following 6 h apigenin treatment**

Lysates from THP-1 cells cultured with 50 µM apigenin for 6 h following 1 h pretreatment with 10 µM of the p38 pharmacological inhibitor SB203580 (*lane 3*), the PKCδ inhibitor rottlerin (*lane 4*), or both (*lane 5*). Immunoblots with phospho-Hsp27 Ser82 and total Hsp27. Densitometry data normalized by the loading control is represented as Mean ± SEM (N=6, * p ≤ 0.01 and ** p ≤ 0.05)
determine PKCδ’s ability to phosphorylate Hsp27 (Fig 3.7). As expected, we found that PKCδ could not phosphorylate Hsp27 at Ser-78. In contrast, we found that PKCδ can directly phosphorylate Hsp27 at Ser-82. Together these findings suggest that PKCδ can phosphorylate Hsp27 selectively at Ser-82 in vitro.

PKCδ has also been shown to act upstream of p38 activation (69). Therefore, we next sought to determine the relationship between PKCδ and p38 in apigenin-induced Hsp27 phosphorylation. For this purpose, THP-1 cells were treated with pharmalogical inhibitors of p38 and PKCδ as indicated above followed by 6 h treatment with apigenin. Cell lysates were prepared and first analyzed by immunoblot analysis (Fig 3.8A). We found that while the p38 inhibitor SB203580 expectantly reduces p38 phosphorylation (lane 3), the PKCδ inhibitor rottlerin fails to reduce p38 phosphorylation (lane 4), indicating that PKCδ is not an upstream regulator of p38 activation following 6 h apigenin treatment. We also analyzed the same samples by in vitro kinase assay to determine PKCδ’s kinase activity following pretreatment with p38 and PKCδ pharmalogical inhibitors (Fig 3.8B). As expected, we found that pretreatment with the PKCδ inhibitor rottlerin decreased PKCδ kinase activity following 6 h apigenin treatment (lane 5). Interestingly, pretreatment with the p38 inhibitor SB203580 (lane 4) also decreased PKCδ kinase activity, suggesting that p38 may act upstream to PKCδ and may provide an additional pathway through which p38 regulates Hsp27 phosphorylation.

3.5 The effect of PKCδ on Hsp27 phosphorylation is independent of ERK activation

As stated, ERK has been identified as both a kinase directly involved in the phosphorylation of MK2 (71) and as a substrate of PKCδ (72). Additionally, our results
Figure 3.7 PKCδ selectively phosphorylates Hsp27 at Ser-82 in vitro.

Recombinant PKCδ (+) or heat-inactivated recombinant PKCδ (-) was incubated with recombinant wild-type Hsp27 and [γ^{32}P]ATP. Phospholabeled proteins were visualized by autoradiography. Immunoblots with phospho-Hsp27 Ser78, phospho-Hsp27 Ser82, total Hsp27, and PKCδ.
Figure 3.8 p38 acts upstream of PKCδ following 6 h apigenin treatment.

Lysates from THP-1 cells cultured with 50 µM apigenin for 6 h following 1 h pretreatment with 10 µM of the p38 pharmacological inhibitor SB203580 (lane 3 [A], lane 4 [B]), the PKCδ inhibitor rottlerin (lane 4 [A], lane 5 [B]), or both (lane 5 [A], lane 6 [B]). (A) Immunoblots with phospho-p38, p38 total, and β-Tubulin. (B) In vitro kinase assays of IP-PKCδ in the presence of H2B and [γ32P]ATP. Immunoblots with PKCδ served as loading control.
show that ERK phosphorylation is greatest at 6 h following apigenin treatment, indicating a potential role for ERK in apigenin-induced Hsp27 phosphorylation at 6 h. In order to assess the role of ERK in Hsp27 phosphorylation we first sought to determine if ERK was a downstream target of PKCδ. For this purpose, we sought to determine the effects of pharmacological inhibition of PKCδ on ERK phosphorylation 6 h post-apigenin treatment. THP-1 cells were pretreated with 15 μM of the PKCδ inhibitor rottlerin or with DMSO as diluent control for 1 h. Following pretreatment, cells were treated with 50 μM apigenin for 6 h. Cell lysates were prepared and analyzed by immunoblot analysis (Fig 3.9A). We found that inhibition of PKCδ with rottlerin reduced ERK phosphorylation following 6 h apigenin treatment (lane 3), identifying ERK as a potential downstream effector of PKCδ during apigenin-induced apoptosis.

To further assess the relationship between PKCδ and ERK we sought to determine the effects of pharmacological inhibition of ERK on Hsp27 phosphorylation. THP-1 cells were pretreated with 25 μM of the ERK inhibitor PD98059 or with DMSO as diluent control for 1 h. Following pretreatment, cells were treated with 50 μM apigenin for 6 h. Cell lysates were prepared and analyzed by immunoblot analysis (Fig 3.9B). We found that inhibition of ERK did not reduce Hsp27 phosphorylation at Ser-78 and Ser-82 (lane 3). These findings suggest that a role for PKCδ in Hsp27 phosphorylation is independent of ERK, further providing evidence that PKCδ may directly phosphorylate Hsp27 during apigenin-induced apoptosis.
Figure 3.9 PKC\(\delta\) effect on Hsp27 phosphorylation is independent of the downstream target ERK

Lysates from THP-1 cells cultured with 50 \(\mu\)M apigenin for 6 h following 1 h pretreatment with (A) 15 \(\mu\)M of the PKC\(\delta\) inhibitor rottlerin (lane 3) or (B) 25 \(\mu\)M of the ERK pharmalogical inhibitor PD98059 (lane 3). Immunoblots with phospho-Hsp27 Ser-78, phospho-Hsp27 Ser-82, phospho-ERK, total Hsp27, total ERK and \(\beta\)-Tubulin.
3.6 Generation of the PKCδ constitutively active catalytic fragment is not necessary for Hsp27 phosphorylation.

PKCδ has been shown to phosphorylate and activate caspase-3 (30). PKCδ has also been identified as a substrate of caspase-3 and its proteolytic cleavage results in a constitutively active catalytic domain necessary for apoptosis (31, 32). Therefore, caspase-3 may play a role in Hsp27 phosphorylation through PKCδ proteolytic activation. We first sought to determine the effect of inhibition of caspase-3 activity on PKCδ kinase activity. THP-1 cells were pretreated with 25 μM of the caspase-3 inhibitory peptide DEVD-FMK or with DMSO as diluent control for 1 h. Following pretreatment, cells were treated with 50 μM apigenin for 6 h. Cell lysates were prepared and analyzed by an in vitro kinase assay to determine PKCδ’s kinase activity following pretreatment with the caspase-3 inhibitor (Fig 3.10A). We found that inhibition of caspase-3 activity decreases PKCδ kinase activity (lane 4), suggesting that PKCδ does not get cleaved to its constitutively active catalytic fragment in the presence of the caspase-3 inhibitory peptide. To further assess the role of caspase-3, we determined the effects of inhibition of caspase-3 activation on Hsp27 phosphorylation. THP-1 cells were treated with the inhibitory peptide of caspase-3 as indicated above followed by 6 h treatment with apigenin. Cell lysates were prepared and analyzed by immunoblot analysis (Fig 3.10B). We found that inhibition of caspase-3 activity failed to reduce Hsp27 phosphorylation at both serine residues, as well as p38 phosphorylation (lane 3), indicating that caspase-3 activity is not necessary for Hsp27 phosphorylation. DEVD-AFC analysis of these samples confirms the efficiency of caspase-3 inhibition.
Figure 3.10 PKCδ activity, but not Hsp27 and p38 phosphorylation, is dependent on caspase-3 activity following 6 h apigenin treatment

Lysates from THP-1 cells cultured with 50 µM apigenin for 6 h following 1 hr pretreatment with 25 µM of the caspase-3 inhibitory peptide DEVD-FMK (lane 3 [A, B], lane 4 [C]). (A) In vitro kinase assays of IP-PKCδ in the presence of H2B and [γ³²P]ATP. (B) Immunoblots with phospho-Hsp27 Ser78, phospho-Hsp27 Ser82, phospho-p38, total Hsp27, total p38 and β-Tubulin. (C) DEVD-AFC analysis of caspase-3 activity.
(Fig 3.10C). Together these results suggest that the non-constitutively active full-length PKCδ may phosphorylate Hsp27 at Ser-82 following apigenin treatment.
CHAPTER 4

ROLE OF HSP27 PHOSPHORYLATION DURING APIGENIN-INDUCED APOPTOSIS

Mitochondrial membrane depolarization occurs within minutes of exposure to apoptotic stimuli as a consequence of the mitochondrial permeability transition pore opening, preceding many other characteristic biochemical changes of apoptosis and serving as a point of no return of the apoptotic pathway (78). As a potent apoptotic stimulus, apigenin has been shown to induce mitochondrial membrane depolarization (46). Hsp27 is known to exhibit its anti-apoptotic activity at various points in the apoptotic pathway. One of the earliest anti-apoptotic functions of Hsp27 is its ability to prevent mitochondrial membrane depolarization (57). Therefore, Hsp27 may protect against apigenin-induced mitochondrial depolarization. Moreover, given that large, non-phosphorylated Hsp27 oligomers have been suggested to be required for Hsp27’s anti-apoptotic function (65), phosphorylation of Hsp27 may directly affect the protein’s ability to protect against mitochondrial depolarization and apoptosis. In this aim, we begin to study the role phosphorylation of Hsp27 plays during apigenin-induced phosphorylation.
4.1 Introduction of Hsp27 mutants into the 6xHis-tagged expression vector pQE32 and protein purification under denaturing conditions.

For future use to characterize Hsp27 direct interaction and association with targets, phospho-null Hsp27 3A (S15A, S78A, S82A) and phospho-mimic Hsp27 3D (S15D, S78D, S82D) recombinant proteins were prepared. For this purpose, the Hsp27 3A and Hsp27 3D clones were excised from a pENTR/D-TOPO vector and introduced into a pQE32 vector in order to add a 6xHis-tag that can be used for affinity purification (Fig 4.1). The pENTR/D-TOPO vector is used to create clones using topoisomerase to ligate a small insert with only one small sticky end. Traditionally, the vector is used for recombination into a destination vector, such as pQE32. From glycerol stocks, bacterial colonies containing pENTR/D-TOPO-Hsp27 3A (AB566) and pENTR/D-TOPO-Hsp27 3D (AB567), as well as pQE32 plasmids (AB262) were grown on antibiotic-resistant agar plates. From select colonies, plasmid DNA was isolated and digested with Bam HI and Sal 1 (Fig 4.2A) resulting in cut pQE32 (lane 1), Hsp27 3A fragment (lane 2, 648 bp), and Hsp27 3D fragment (lane 3, 648 bp). DNA extraction from the agarose gel yielded purified linearized pQE32, Hsp27 3A insert, and Hsp27 3D insert (Fig 4.2B). Following DNA extraction, linearized pQE32 was ligated to Hsp27 3A and Hsp27 3D inserts in the presence of T4 ligase. The ligation was used to transform E. coli Top10F competent cells, and colonies were selected on LB-agar plates containing ampicillin. DNA was purified and screened by sequencing and restriction enzyme analysis with Bam HI and Sal 1 (Fig 4.2C) with positive clones yielding inserts of 648 bp (lane 1,2,3 [pQE32-Hsp27 3A], lane 5,6 [pQE32-Hsp27 3D])

E. coli containing clones pQE32-Hsp27 3A and pQE32-Hsp27 3D was used for protein purification. Expression of 6xHis-tagged Hsp27 phospho-
Figure 4.1 Experimental scheme.
Figure 4.2 Ligation of Hsp27 3A and Hsp27 3D into the 6xHis-tagged pQE 32 vector

(A) pQE 32, Topo-Hsp27 3A, Topo-Hsp27 3D were digested with Bam HI and Sal 1. (B) DNA extraction from the agarose gel yielded purified cut pQE32 and Hsp27 3A and Hsp27 3D inserts. (C) Following ligation of pQE32:Hsp27 3A and pQE32:Hsp27 3D and transformation into *E. coli* Top10F competent cells, restriction digestion with Bam HI and Sal 1 identified positive clones (*lane 1,2,3* [pQE32-Hsp27 3A], *lane 5,6* [pQE32-Hsp27 3D])
mutants was induced using IPTG and recombinant Hsp27 3A-6xHis and Hsp27 3D-6xHis was purified from bacteria using a Ni\(^{2+}\)-NTA affinity column (see Material and Methods). Using increasingly acidic buffers, substantial amount of protein was obtained in the first two elutions with buffer E (Fig 4.3A lanes 12, 13). Following dialysis and refolding, elution fractions containing mutant Hsp27 were analyzed by SDS-PAGE and quantitated by coomassie staining against a BSA gradient (Fig 4.3B) and identified by immunoblot with total Hsp27 (Fig 4.3C).

4.2 Phosphorylation of Hsp27 is not required for Hsp27’s ability to protect against apigenin-induced mitochondrial membrane depolarization.

Hsp27 is able to block apoptosis at different stages because of its interaction with different partners. The capacity of Hsp27 to interact with one or another partner seems to be determined by the oligomerization and phosphorylation status of the protein. At the earliest stages of apoptosis, Hsp27 is known to prevent mitochondrial depolarization through the suppression ROS formation by inhibiting PKC\(\delta\) and upholding glutathione in its reduced form (34, 59). Therefore, phosphorylation of Hsp27 may serve to regulate Hsp27’s ability to prevent mitochondrial membrane depolarization. For this purpose, we sought to determine the effect of transfection of DNA encoding wild-type Hsp27, phospho-null Hsp27 3A and phospho-mimic Hsp27 3D into THP-1 cells on membrane depolarization. Twenty-four hours after transfection of empty vector (pCDNA3-5myc), vector containing wild type full-length Hsp27 (pCDNA3-Hsp27-wt-FL-5myc), full-length Hsp27 3A (pCDNA3-Hsp27-3A-FL-5myc), or full-length Hsp27 3D (pCDNA3-Hsp27-3D-FL-5myc), cells were treated with 50 \(\mu\)M apigenin for 1 h. Cells were then fixed with the mitochondrial membrane potential specific fluorescent probe JC-1 and
Figure 4.3 Purification of 6xHis-tagged Hsp27 under denaturing conditions

(A) Coomassie stain of the purification of Hsp27 clones using a Ni$^{2+}$-affinity column with elutions in a discontinuous pH gradient (buffer D pH 5.9; buffer E pH 4.5). Following refolding, elution fractions containing mutant Hsp27 were analyzed by SDS-PAGE and (B) quantitated by coomassie staining against a BSA standard and (C) immunoblotted with total Hsp27.
analyzed by flow cytometry to detect color shifts in the dye upon formation of JC-1 aggregates accompanying membrane depolarization (Fig 4.4). We found that apigenin treatment for 1 h increases mitochondrial membrane potential by 27% (Fig 4.4A). As expected, we found that introduction of Hsp27 wt-FL reduces mitochondrial depolarization to 6% (Fig 4.4B). Interestingly, we also found that both Hsp27 3A-FL and Hsp27 3D-FL (Fig 4.4C, Fig 4.4D, respectively) are able to reduce mitochondrial depolarization in the same magnitude, suggesting that phosphorylation of Hsp27 is not required for the protein’s ability to protect against apigenin-induced mitochondrial depolarization.
Figure 4.4 Hsp27’s ability to protect against mitochondrial depolarization is independent of its phosphorylation status

THP-1 cells were transfected with (A) empty vector, (B) vector containing Hsp27-wt-FL, (C) Hsp27 3A (S15A-S78A-S82A), or (D) Hsp27 3D (S15D-S78D-S82D) and cultured with 50 µM apigenin for 1 h. Cells were fixed with JC-1 and analyzed by FACS analysis to determine changes in mitochondrial membrane potential.
CHAPTER 5
DISCUSSION

Hsp27 is a chaperone that exhibits many anti-apoptotic functions. Central to Hsp27 anti-apoptotic function is the dynamic relationship between phosphorylation, oligomerization, and association with target proteins (55, 66, 73, 74). In particular, Hsp27 is known to regulate many of the molecules involved in caspase-dependent apoptosis (60-63). During caspase-dependent apoptosis, external signals transduced through death receptors or internal signals transduced through mitochondrial dysfunction generate a signaling cascade that culminates in the proteolytic activation of effector caspases responsible for facilitating the characteristic biochemical changes observed during apoptosis (3). Among the signals more commonly responsible for apoptosis are cytotoxic drugs. Recently, our lab identified a plant flavonoid, apigenin, that has anti-cancer and anti-inflammatory properties (47). We showed that apigenin is a potent pro-apoptotic molecule in leukemia cells through localization to the mitochondria and induction of apoptosis in a PKCδ and caspase-dependent manner. In this work, we built on the model of apigenin-induced apoptosis with an emphasis on the regulation and role of Hsp27 phosphorylation.

Since many of the functions attributed to Hsp27 require its phosphorylation (74, 79, 80), the identification of the protein kinases that mediate Hsp27 phosphorylation is critical for understanding the regulation of Hsp27’s multiple cellular functions. The mitogen-activated protein kinase p38 is known to be activated in response to chemotherapeutic drugs as a pro-apoptotic molecule (26) and is widely regarded as an upstream kinase of Hsp27 through activation of MK2 (81). Thus, p38 was investigated as
a potential kinase involved in apigenin-induced Hsp27 phosphorylation. Accordingly, we demonstrate that Hsp27 phosphorylation at Ser-78 and Ser-82 is p38 dependent following 15 min and 6 h apigenin treatment (Fig 3.4 – Fig 3.6). In addition, we exhibit that p38 activity following 6 h apigenin treatment is independent of caspase-3 activity (Fig 3.10B), consistent with findings that p38 activity is not essential for apigenin-induced apoptosis (47). PKCδ has also been implicated in Hsp27 phosphorylation, albeit in a stimulus-dependent manner (82). PKCδ can act as either pro-apoptotic molecule or anti-apoptotic molecule depending on the stimulus (77). Our lab has shown that PKCδ associates with and phosphorylates caspase-3, promoting apoptosis (30). Here, we identified a role for PKCδ in apigenin-induced Hsp27 phosphorylation. We demonstrate that PKCδ can directly and selectively phosphorylate Hsp27 at Ser-82 (Fig 3.7). We also find that PKCδ may act downstream of p38 in a pathway parallel to p38 activation of MK2 at 6 h post-apigenin treatment (Fig. 3.8B). In addition, we find that PKCδ exhibits its effect on Hsp27 phosphorylation independent of both downstream ERK (Fig 3.9) and cleavage by caspase-3 (Fig 3.10), suggesting that full-length PKCδ may directly phosphorylate Hsp27 at Ser-82 following 6 h apigenin treatment as a result of p38 activation.

The role played by Hsp27 as an anti-apoptotic molecule appears to be largely determined by its oligomerization and thus, phosphorylation state. It has been suggested that large non-phosphorylated oligomers are the structural organization required for Hsp27’s caspase-dependent anti-apoptotic activity (65). However, phosphorylation of Hsp27 results in a shift from large, nonphosphorylated oligomers to smaller phosphorylated multimers such as dimers and this shift attenuates Hsp27’s affinity for its
substrates (74). Therefore, phosphorylation may disrupt the anti-apoptotic activity of Hsp27. However, our findings suggest that Hsp27’s ability to protect against apigenin-induced mitochondrial membrane depolarization (Fig 4.4) is independent of the protein’s phosphorylation state. We find that the Hsp27 wt can protect against apigenin-induced mitochondrial depolarization. Moreover, phospho-null Hsp27 3A mutant and phospho-mimic Hsp27 3D mutant have similar cytoprotective abilities. Therefore; results are consistent with previous suggestions that large non-phosphorylated oligomers are required for Hsp27’s anti-apoptotic activity at this early event.

According to our model of apigenin-induced apoptosis, Hsp27 is phosphorylated at both Ser-78 and Ser-82 by p38 through MK2 at 15 min and 6 h and at Ser-82 by p38 through PKCδ at 6 h. The bimodal phosphorylation of Hsp27 during apigenin-induced apoptosis is a distinct mechanism of Hsp27 regulation. The underlying significance of our findings is that different methods of regulation of Hsp27 phosphorylation could result in different fates for the phosphorylated molecule. Our findings suggest that early and late phosphorylation of Hsp27 following apigenin treatment represent distinct, and perhaps mechanistically important, roles for the phosphorylated molecule in response to apigenin-induced apoptosis. Apigenin-induced early phosphorylation may play either an anti-apoptotic or pro-apoptotic role within the cell. Upon phosphorylation by the p38 MAPK pathway, Hsp27 has been shown to protect cells from oxidative stress by upholding glutathione in its reduced form (83) as well as stabilizing actin filament dynamics following stress (80, 84). These functions may protect the cell against mitochondrial dysfunction as both oxidative stress and actin destabilization contribute to mitochondrial dysfunction and apoptosis (85, 86). However, our results indicate that
Hsp27 phosphorylation is not essential for the protein’s ability to protect against mitochondrial depolarization, suggesting that early Hsp27 phosphorylation may be a stress response rather than an anti-apoptotic response. Additionally, early Hsp27 phosphorylation may play a pro-apoptotic role through its ability to cause dissociation of the molecule from its target proteins. In particular, Hsp27 phosphorylation may play a role in dissociation from its target proteins during caspase-dependent apoptosis. Our lab has shown using recombinant proteins that cleavage of the prodomain of caspase-3 occurs as early as 45 min following the addition of caspase-9 and that addition of Hsp27 attenuates this cleavage (64). Therefore, early phosphorylation of Hsp27 may play a role in promoting caspase-dependent apoptosis by alleviating Hsp27 inhibition of caspase-3.

In addition, our lab has shown that Hsp27 is found mostly in the nucleus at 8 h during spontaneous monocyte apoptosis. This may suggest a role for the late Hsp27 phosphorylation as phosphorylation of Hsp27 has been shown to affect the protein’s ability to translocate to the nucleus (79, 87). Additionally, the ability to selectively phosphorylate Hsp27 at either Ser-78 or Ser-82 following 6 h apigenin treatment could result in drastically different cellular fates. Indeed, specific phosphorylation of Hsp27 at Ser-78 or Ser-82 has been shown to play integral roles in cellular fate (88-90). Therefore, the phosphorylation of Hsp27 at Ser-82 by PKCδ may play a yet uncharacterized role in Hsp27 regulation. Interestingly, it has been shown that dissociation of PMA-induced Hsp27 aggregates can be prevented by PKC inhibitors, while p38 inhibitors achieve a significantly smaller effect (82). Thus, PKCδ phosphorylation at Ser-82 may play an essential role in the regulation of Hsp27 through phosphorylation-induced dissociation of
Hsp27 into smaller multimers and dissociation of the molecule from a yet unidentified target at this time.

The pro-apoptotic roles of apigenin highlight the ever growing focus on chemopreventive roles of naturally-derived dietary compounds such as flavonoids. As an antioxidant, apigenin serve to regulate intracellular redox balance. However, apigenin is also potent inducer of the apoptotic pathway and the study of apigenin-induced apoptosis helps us to understand the molecular mechanisms flavonoids use to regulate cell fate and the potential use of flavonoids as chemotherapeutic agents.
Figure 5.1 Working Model
ACKNOWLEDGEMENTS

Thanks to Dr. Andrea Doseff for her guidance, opportunity, contribution, and critical reading of this thesis. Thanks also to Dr. Martha Elba Gonzalez-Mejia and Oliver Voss for their contributions to this work, and the Doseff lab members for their aid and support. This research was supported by RO1HL075040-01 and NSF-MCB-0542244 to AID and the OSU College of Biological Sciences Dean’s Undergraduate Research Fund and Mayer’s Summer Research Internship to EJM.
REFERENCES


